When Huiminbao, or the "people-benefiting insurance scheme" was first rolled out in China, few believed the new and low-cost coverage program would be able to solve the biggest issue facing the vast patient population in the country - affordable access to innovative new drugs.
Multinational pharma firms nevertheless hopped onboard, many of them having turned away from rounds of deep-cutting price negotiations initiated by the Chinese government in exchange for